Identification

Name
Domperidone
Accession Number
DB01184  (APRD00418)
Type
Small Molecule
Groups
Approved, Investigational, Vet Approved
Description

A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms. [PubChem]

Structure
Thumb
Synonyms
  • 1-(3-(4-(5-chloro-2-oxo-2,3-Dihydrobenzo[D]imidazol-1-yl)piperidin-1-yl)propyl)-1H-benzo[D]imidazol-2(3H)-one
  • 5-chloro-1-(1-(3-(2-oxo-1-Benzimidazolinyl)propyl)-4-piperidyl)-2-benzimidazolinone
  • 5-chloro-1-(1-(3-(2-oxo-2,3-Dihydrobenzo[D]imidazol-1-yl)propyl)piperidin-4-yl)-1H-benzo[D]imidazol-2(3H)-one
  • 5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-benzoimidazol-1-yl)-propyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one
  • Domperidona
  • Domperidonum
External IDs
R 33,812 / R-33812
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ava-domperidoneTablet10 mgOralAvanstra Inc2011-09-152014-08-21Canada
Bio-domperidoneTablet10 mgOralBiomed Pharma2016-04-26Not applicableCanada
Dom-domperidoneTablet10 mgOralDominion Pharmacal1998-09-17Not applicableCanada
DomperidoneTablet10 mgOralRanbaxy Inc.Not applicableNot applicableCanada
DomperidoneTablet10 mgOralSivem Pharmaceuticals Ulc1998-09-03Not applicableCanada
DomperidoneTablet10 mgOralSanis Health Inc2010-05-12Not applicableCanada
Domperidone-10Tablet10 mgOralPro Doc Limitee1998-07-13Not applicableCanada
Ftp-domperidone MaleateTablet10 mgOralGmd Distribution Inc.1998-10-092005-08-05Canada
Ipg-domperidoneTablet10 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-domperidoneTablet10 mgOralJamp Pharma Corporation2011-10-07Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-domperidone - Tab 10mgTablet10 mgOralApotex Corporation1997-09-17Not applicableCanada
International/Other Brands
Euciton (Roux-Ocefa) / Moperidona (Sidus) / Motilium (Janssen) / Nauzelin (Kyowa Hakko Kirin)
Categories
UNII
5587267Z69
CAS number
57808-66-9
Weight
Average: 425.911
Monoisotopic: 425.161852744
Chemical Formula
C22H24ClN5O2
InChI Key
FGXWKSZFVQUSTL-UHFFFAOYSA-N
InChI
InChI=1S/C22H24ClN5O2/c23-15-6-7-20-18(14-15)25-22(30)28(20)16-8-12-26(13-9-16)10-3-11-27-19-5-2-1-4-17(19)24-21(27)29/h1-2,4-7,14,16H,3,8-13H2,(H,24,29)(H,25,30)
IUPAC Name
5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-1H-1,3-benzodiazol-1-yl)propyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one
SMILES
ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=CC=CC=C34)CC1)C(=O)N2

Pharmacology

Indication

For management of dyspepsia, heartburn, epigastric pain, nausea, and vomiting.

Structured Indications
Pharmacodynamics

Domperidone is a specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.

Mechanism of action

Domperidone acts as a gastrointestinal emptying (delayed) adjunct and peristaltic stimulant. The gastroprokinetic properties of domperidone are related to its peripheral dopamine receptor blocking properties. Domperidone facilitates gastric emptying and decreases small bowel transit time by increasing esophageal and gastric peristalsis and by lowering esophageal sphincter pressure. Antiemetic: The antiemetic properties of domperidone are related to its dopamine receptor blocking activity at both the chemoreceptor trigger zone and at the gastric level. It has strong affinities for the D2 and D3 dopamine receptors, which are found in the chemoreceptor trigger zone, located just outside the blood brain barrier, which - among others - regulates nausea and vomiting

TargetActionsOrganism
AD(2) dopamine receptor
antagonist
Human
AD(3) dopamine receptor
antagonist
Human
Absorption

Fast

Volume of distribution
Not Available
Protein binding

91%-93%

Metabolism
Route of elimination
Not Available
Half life

7 hours

Clearance
Not Available
Toxicity

Side effects include galactorrhea, gynecomastia, or menstrual irregularities.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Domperidone.Experimental
AbirateroneThe serum concentration of Domperidone can be increased when it is combined with Abiraterone.Approved
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
AmantadineAmantadine may increase the QTc-prolonging activities of Domperidone.Approved
AmiodaroneThe serum concentration of Domperidone can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Domperidone.Approved
AmoxapineAmoxapine may increase the QTc-prolonging activities of Domperidone.Approved
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Domperidone.Approved, Illicit
AnagrelideThe risk or severity of QTc prolongation can be increased when Anagrelide is combined with Domperidone.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
AprepitantThe serum concentration of Domperidone can be increased when it is combined with Aprepitant.Approved, Investigational
ArformoterolArformoterol may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
Arsenic trioxideThe risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Domperidone.Approved, Investigational
ArtemetherThe metabolism of Domperidone can be decreased when combined with Artemether.Approved
AsenapineThe risk or severity of QTc prolongation can be increased when Domperidone is combined with Asenapine.Approved
AtazanavirThe serum concentration of Domperidone can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe serum concentration of Domperidone can be increased when it is combined with Atomoxetine.Approved
AzithromycinThe metabolism of Domperidone can be decreased when combined with Azithromycin.Approved
BedaquilineBedaquiline may increase the QTc-prolonging activities of Domperidone.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Domperidone.Withdrawn
BetaxololThe metabolism of Domperidone can be decreased when combined with Betaxolol.Approved
BoceprevirThe serum concentration of Domperidone can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe serum concentration of Domperidone can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Domperidone can be decreased when it is combined with Bosentan.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Domperidone.Experimental
BupropionThe metabolism of Domperidone can be decreased when combined with Bupropion.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Domperidone.Approved
CaffeineThe metabolism of Domperidone can be decreased when combined with Caffeine.Approved
CarbamazepineThe metabolism of Domperidone can be increased when combined with Carbamazepine.Approved, Investigational
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Domperidone.Withdrawn
CelecoxibThe metabolism of Domperidone can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Domperidone can be increased when it is combined with Ceritinib.Approved
ChloroquineThe metabolism of Domperidone can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe metabolism of Domperidone can be decreased when combined with Chlorpromazine.Approved, Vet Approved
CholecalciferolThe metabolism of Domperidone can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Domperidone can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Domperidone can be decreased when combined with Cinacalcet.Approved
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
CisaprideThe risk or severity of QTc prolongation can be increased when Cisapride is combined with Domperidone.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Domperidone can be decreased when combined with Citalopram.Approved
ClarithromycinThe serum concentration of Domperidone can be increased when it is combined with Clarithromycin.Approved
ClemastineThe serum concentration of Domperidone can be increased when it is combined with Clemastine.Approved
ClobazamThe metabolism of Domperidone can be decreased when combined with Clobazam.Approved, Illicit
ClomipramineClomipramine may increase the QTc-prolonging activities of Domperidone.Approved, Vet Approved
ClopidogrelThe metabolism of Domperidone can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClotrimazoleThe serum concentration of Domperidone can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Domperidone can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Domperidone can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Domperidone can be decreased when combined with Cocaine.Approved, Illicit
ConivaptanThe serum concentration of Domperidone can be increased when it is combined with Conivaptan.Approved, Investigational
CrisaboroleThe metabolism of Domperidone can be decreased when combined with Crisaborole.Approved
CrizotinibThe serum concentration of Domperidone can be increased when it is combined with Crizotinib.Approved
CyclosporineThe serum concentration of Domperidone can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Domperidone can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Domperidone can be decreased when it is combined with Dabrafenib.Approved
DarifenacinThe metabolism of Domperidone can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Domperidone can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Domperidone can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Domperidone can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Domperidone.Approved
DelavirdineThe serum concentration of Domperidone can be increased when it is combined with Delavirdine.Approved
DesfluraneDesflurane may increase the QTc-prolonging activities of Domperidone.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Domperidone.Approved
DihydroergotamineThe serum concentration of Domperidone can be increased when it is combined with Dihydroergotamine.Approved
DiltiazemThe serum concentration of Domperidone can be increased when it is combined with Diltiazem.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Domperidone.Approved
DisopyramideThe risk or severity of QTc prolongation can be increased when Disopyramide is combined with Domperidone.Approved
DofetilideThe risk or severity of QTc prolongation can be increased when Dofetilide is combined with Domperidone.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Domperidone.Approved
DosulepinThe metabolism of Domperidone can be decreased when combined with Dosulepin.Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Domperidone.Approved
DoxorubicinThe metabolism of Domperidone can be decreased when combined with Doxorubicin.Approved, Investigational
DoxycyclineThe serum concentration of Domperidone can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe serum concentration of Domperidone can be increased when it is combined with Dronedarone.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Domperidone.Approved, Vet Approved
DuloxetineThe metabolism of Domperidone can be decreased when combined with Duloxetine.Approved
EfavirenzThe metabolism of Domperidone can be decreased when combined with Efavirenz.Approved, Investigational
EliglustatThe metabolism of Domperidone can be decreased when combined with Eliglustat.Approved
EnzalutamideThe serum concentration of Domperidone can be decreased when it is combined with Enzalutamide.Approved
EribulinEribulin may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
ErythromycinThe serum concentration of Domperidone can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of QTc prolongation can be increased when Escitalopram is combined with Domperidone.Approved, Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Domperidone.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Domperidone.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Domperidone.Approved
FelodipineThe metabolism of Domperidone can be decreased when combined with Felodipine.Approved, Investigational
FingolimodFingolimod may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Domperidone.Approved, Withdrawn
FluconazoleThe serum concentration of Domperidone can be increased when it is combined with Fluconazole.Approved
FluoxetineThe metabolism of Domperidone can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of QTc prolongation can be increased when Flupentixol is combined with Domperidone.Approved, Withdrawn
FluvoxamineThe serum concentration of Domperidone can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
FosamprenavirThe serum concentration of Domperidone can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Domperidone can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Domperidone.Approved
FosphenytoinThe metabolism of Domperidone can be increased when combined with Fosphenytoin.Approved
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Domperidone.Approved, Investigational, Vet Approved
Fusidic AcidThe serum concentration of Domperidone can be increased when it is combined with Fusidic Acid.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Domperidone.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Domperidone.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
GoserelinGoserelin may increase the QTc-prolonging activities of Domperidone.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
HaloperidolThe metabolism of Domperidone can be decreased when combined with Haloperidol.Approved
HarmalineThe risk or severity of adverse effects can be increased when Harmaline is combined with Domperidone.Experimental
HistrelinHistrelin may increase the QTc-prolonging activities of Domperidone.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Domperidone.Experimental
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Domperidone.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
IbutilideThe risk or severity of QTc prolongation can be increased when Ibutilide is combined with Domperidone.Approved
IdelalisibThe serum concentration of Domperidone can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of QTc prolongation can be increased when Domperidone is combined with Iloperidone.Approved
ImatinibThe serum concentration of Domperidone can be increased when it is combined with Imatinib.Approved
ImipramineImipramine may increase the QTc-prolonging activities of Domperidone.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Domperidone.Approved
IndapamideIndapamide may increase the QTc-prolonging activities of Domperidone.Approved
IndinavirThe serum concentration of Domperidone can be increased when it is combined with Indinavir.Approved
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Domperidone.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Domperidone.Withdrawn
IrbesartanThe metabolism of Domperidone can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe serum concentration of Domperidone can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Domperidone.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Domperidone.Approved, Vet Approved
IsoniazidThe metabolism of Domperidone can be decreased when combined with Isoniazid.Approved
IsradipineThe serum concentration of Domperidone can be increased when it is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Domperidone can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Domperidone.Approved
IvacaftorThe serum concentration of Domperidone can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe serum concentration of Domperidone can be increased when it is combined with Ketoconazole.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
LenvatinibLenvatinib may increase the QTc-prolonging activities of Domperidone.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
LidocaineThe metabolism of Domperidone can be decreased when combined with Lidocaine.Approved, Vet Approved
LithiumLithium may increase the QTc-prolonging activities of Domperidone.Approved
LobeglitazoneThe metabolism of Domperidone can be decreased when combined with Lobeglitazone.Approved, Investigational
LopinavirThe serum concentration of Domperidone can be increased when it is combined with Lopinavir.Approved
LorcaserinThe metabolism of Domperidone can be decreased when combined with Lorcaserin.Approved
LosartanThe metabolism of Domperidone can be decreased when combined with Losartan.Approved
LovastatinThe serum concentration of Domperidone can be increased when it is combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Domperidone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Domperidone can be increased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Domperidone can be decreased when combined with Lumefantrine.Approved
ManidipineThe metabolism of Domperidone can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Domperidone.Approved
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Domperidone.Withdrawn
MefloquineMefloquine may increase the QTc-prolonging activities of Domperidone.Approved
MethadoneThe metabolism of Domperidone can be decreased when combined with Methadone.Approved
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Domperidone.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Domperidone.Approved, Investigational
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
MetoprololThe metabolism of Domperidone can be decreased when combined with Metoprolol.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Domperidone.Approved
MexiletineThe metabolism of Domperidone can be decreased when combined with Mexiletine.Approved
MidostaurinThe metabolism of Domperidone can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Domperidone can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Domperidone.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Domperidone.Approved
MirtazapineMirtazapine may increase the QTc-prolonging activities of Domperidone.Approved
MitotaneThe serum concentration of Domperidone can be decreased when it is combined with Mitotane.Approved
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Domperidone.Approved
MoexiprilMoexipril may increase the QTc-prolonging activities of Domperidone.Approved
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
NefazodoneThe serum concentration of Domperidone can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Domperidone can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Domperidone can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Domperidone can be increased when it is combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Domperidone.Withdrawn
NicardipineNicardipine may increase the QTc-prolonging activities of Domperidone.Approved
NilotinibThe serum concentration of Domperidone can be increased when it is combined with Nilotinib.Approved, Investigational
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Domperidone.Approved
NortriptylineNortriptyline may increase the QTc-prolonging activities of Domperidone.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Domperidone.Withdrawn
OctreotideOctreotide may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Domperidone.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
OlaparibThe serum concentration of Domperidone can be increased when it is combined with Olaparib.Approved
OlodaterolOlodaterol may increase the QTc-prolonging activities of Domperidone.Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Domperidone.Approved
OsimertinibThe serum concentration of Domperidone can be increased when it is combined with Osimertinib.Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Domperidone.Approved, Vet Approved
PalbociclibThe serum concentration of Domperidone can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of QTc prolongation can be increased when Domperidone is combined with Paliperidone.Approved
PanobinostatThe serum concentration of Domperidone can be increased when it is combined with Panobinostat.Approved, Investigational
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Domperidone.Approved
ParoxetineParoxetine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Domperidone.Approved
PazopanibPazopanib may increase the QTc-prolonging activities of Domperidone.Approved
Peginterferon alfa-2bThe serum concentration of Domperidone can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentamidinePentamidine may increase the QTc-prolonging activities of Domperidone.Approved
PentobarbitalThe metabolism of Domperidone can be increased when combined with Pentobarbital.Approved, Vet Approved
PerflutrenPerflutren may increase the QTc-prolonging activities of Domperidone.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Domperidone.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Domperidone.Withdrawn
PhenobarbitalThe metabolism of Domperidone can be increased when combined with Phenobarbital.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Domperidone.Withdrawn
PhenytoinThe metabolism of Domperidone can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of QTc prolongation can be increased when Pimozide is combined with Domperidone.Approved
PioglitazoneThe metabolism of Domperidone can be decreased when combined with Pioglitazone.Approved, Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Domperidone.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Domperidone.Withdrawn
PosaconazoleThe serum concentration of Domperidone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Domperidone.Approved
PrimidoneThe metabolism of Domperidone can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideThe risk or severity of QTc prolongation can be increased when Procainamide is combined with Domperidone.Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Domperidone.Approved
PromazineThe metabolism of Domperidone can be decreased when combined with Promazine.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Domperidone.Approved
PropafenonePropafenone may increase the QTc-prolonging activities of Domperidone.Approved
PropofolPropofol may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Domperidone.Approved
QuazepamThe serum concentration of Domperidone can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of QTc prolongation can be increased when Domperidone is combined with Quetiapine.Approved
QuinidineThe metabolism of Domperidone can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Domperidone can be decreased when combined with Quinine.Approved
RabeprazoleThe metabolism of Domperidone can be decreased when combined with Rabeprazole.Approved, Investigational
RanolazineThe serum concentration of Domperidone can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Domperidone.Approved
RibociclibThe risk or severity of QTc prolongation can be increased when Ribociclib is combined with Domperidone.Approved
RifabutinThe metabolism of Domperidone can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Domperidone can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Domperidone can be increased when combined with Rifapentine.Approved
RilpivirineRilpivirine may increase the QTc-prolonging activities of Domperidone.Approved
RisperidoneRisperidone may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
RitonavirRitonavir may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
RolapitantThe metabolism of Domperidone can be decreased when combined with Rolapitant.Approved
RopiniroleThe metabolism of Domperidone can be decreased when combined with Ropinirole.Approved, Investigational
RosiglitazoneThe metabolism of Domperidone can be decreased when combined with Rosiglitazone.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Domperidone.Withdrawn
SalbutamolSalbutamol may increase the QTc-prolonging activities of Domperidone.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Domperidone.Approved
SaquinavirThe serum concentration of Domperidone can be increased when it is combined with Saquinavir.Approved, Investigational
SecobarbitalThe metabolism of Domperidone can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Domperidone.Approved, Investigational, Vet Approved
SertralineSertraline may increase the QTc-prolonging activities of Domperidone.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Domperidone.Approved, Vet Approved
SildenafilThe serum concentration of Domperidone can be increased when it is combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Domperidone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Domperidone can be increased when it is combined with Simeprevir.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Domperidone.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
SotalolThe risk or severity of QTc prolongation can be increased when Sotalol is combined with Domperidone.Approved
St. John's WortThe serum concentration of Domperidone can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Domperidone can be increased when it is combined with Stiripentol.Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Domperidone.Approved
SulfisoxazoleThe serum concentration of Domperidone can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SunitinibSunitinib may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
TamoxifenTamoxifen may increase the QTc-prolonging activities of Domperidone.Approved
TelaprevirThe serum concentration of Domperidone can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelavancinTelavancin may increase the QTc-prolonging activities of Domperidone.Approved
TelithromycinThe serum concentration of Domperidone can be increased when it is combined with Telithromycin.Approved
Tenofovir disoproxilThe metabolism of Domperidone can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerbinafineThe metabolism of Domperidone can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Domperidone.Approved
TeriflunomideThe serum concentration of Domperidone can be decreased when it is combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of QTc prolongation can be increased when Domperidone is combined with Tetrabenazine.Approved
TheophyllineThe metabolism of Domperidone can be decreased when combined with Theophylline.Approved
ThioridazineThe metabolism of Domperidone can be decreased when combined with Thioridazine.Approved, Withdrawn
ThiotepaThe metabolism of Domperidone can be decreased when combined with Thiotepa.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Domperidone.Approved
TiclopidineThe serum concentration of Domperidone can be increased when it is combined with Ticlopidine.Approved
TipranavirThe metabolism of Domperidone can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Domperidone.Approved
TocilizumabThe serum concentration of Domperidone can be decreased when it is combined with Tocilizumab.Approved
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Domperidone.Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
TopiroxostatThe metabolism of Domperidone can be decreased when combined with Topiroxostat.Approved, Investigational
ToremifeneThe risk or severity of QTc prolongation can be increased when Toremifene is combined with Domperidone.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Domperidone.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Domperidone.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Domperidone.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Domperidone.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Domperidone.Approved, Vet Approved
VandetanibThe risk or severity of QTc prolongation can be increased when Domperidone is combined with Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Domperidone.Approved
VemurafenibThe serum concentration of Domperidone can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe serum concentration of Domperidone can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Domperidone can be increased when it is combined with Verapamil.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Domperidone.Approved
VoriconazoleThe serum concentration of Domperidone can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Domperidone.Approved, Investigational
ZiprasidoneThe serum concentration of Domperidone can be increased when it is combined with Ziprasidone.Approved
ZucapsaicinThe metabolism of Domperidone can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolThe risk or severity of QTc prolongation can be increased when Domperidone is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take 15 to 30 minutes before meals.

References

Synthesis Reference

Vanderberk, J., Kennis, L.E.J., Van der Aa, M.J.M.C. and Van Heertum, A.H.M.T.; U.S. Patents 4,066,772; January 3,1978; 4.1 10,333; August 29,1978; 4,126,687; November 21, 1978; 4,126,688; November 21,1978; 4,160,836; July 10,1979 and 4,175,129; November 20,1979; all assigned to Janssen Pharmaceutica NV (Belgium).

General References
  1. Silvers D, Kipnes M, Broadstone V, Patterson D, Quigley EM, McCallum R, Leidy NK, Farup C, Liu Y, Joslyn A: Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM-USA-5 Study Group. Clin Ther. 1998 May-Jun;20(3):438-53. [PubMed:9663360]
External Links
Human Metabolome Database
HMDB15315
KEGG Drug
D01745
PubChem Compound
3151
PubChem Substance
46508314
ChemSpider
3039
BindingDB
50241107
ChEBI
31515
ChEMBL
CHEMBL219916
Therapeutic Targets Database
DAP001368
PharmGKB
PA134711056
IUPHAR
965
Guide to Pharmacology
GtP Drug Page
Wikipedia
Domperidone
ATC Codes
A03FA03 — Domperidone
AHFS Codes
  • 56:32.00 — Prokinetic Agents
MSDS
Download (73.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentBreastfeeding1
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentIdiopathic orthostatic hypotension / Multiple System Atrophy (MSA) / Parkinson's Disease (PD)1
2CompletedTreatmentLow Milk Supply1
2CompletedTreatmentParkinson's Disease (PD)1
2Enrolling by InvitationTreatmentRelapsing Remitting Multiple Sclerosis (RRMS)1
2RecruitingTreatmentGastroparesis1
2RecruitingTreatmentSecondary Progressive Multiple Sclerosis (SPMS)1
2TerminatedTreatmentGastroparesis1
2TerminatedTreatmentInsufficient Breastmilk Production1
2TerminatedTreatmentParkinson's Disease (PD) / Peripheral Edema1
2, 3CompletedTreatmentLow Breast Milk Supply1
3CompletedTreatmentAcute Gastroenteritis / Gastroenteritis / Vomiting1
3CompletedTreatmentIndigestion1
3CompletedTreatmentParkinson's Disease,Idiopathic1
3RecruitingTreatmentGastroesophageal Reflux Disease / Scleroderma / Sclerosis, Progressive Systemic1
3RecruitingTreatmentGastrointestinal Diseases1
3TerminatedTreatmentGastroenteritis1
3WithdrawnTreatmentGastroesophageal Reflux Disease1
3WithdrawnTreatmentGastroparesis1
4CompletedNot AvailableDeath, Sudden,Cardiac1
4CompletedDiagnosticGastroesophageal Reflux Disease1
4CompletedTreatmentGastroesophageal Reflux Disease1
4Unknown StatusTreatmentDiabetic Gastroparesis1
Not AvailableAvailableNot AvailableGastroesophageal Reflux Disease / Gastroparesis / GERD1
Not AvailableAvailableNot AvailableOncology Patients With Gastroparesis1
Not AvailableAvailableNot AvailableRefractory Gastroesophageal Reflux Disease With Upper Gastrointestinal (GI) Symptoms, Gastroparesis, and Chronic Constipation1
Not AvailableCompletedNot AvailableParkinson's Disease (PD)1
Not AvailableCompletedBasic ScienceDiabetes Mellitus (DM)1
Not AvailableCompletedTreatmentPatients With Gastroparesis Who Have Failed Standard Therapy1
Not AvailableRecruitingTreatmentGastroparesis1
Not AvailableTerminatedTreatmentChronic Idiopathic Constipation / Esophagitis / Gastroparesis / GERD / Indigestion / Nausea / Vomiting1
Not AvailableTerminatedTreatmentDiabetic Gastroparesis1
Not AvailableTerminatedTreatmentGastroparesis / Reflux, Gastroesophageal1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Professional Co.
Dosage forms
FormRouteStrength
TabletOral10 mg
Prices
Unit descriptionCostUnit
Domperidone bp powder55.2USD g
Ratio-Domperidone Maleate 10 mg Tablet0.16USD tablet
Apo-Domperidone 10 mg Tablet0.16USD tablet
Mylan-Domperidone 10 mg Tablet0.16USD tablet
Novo-Domperidone 10 mg Tablet0.16USD tablet
Nu-Domperidone 10 mg Tablet0.16USD tablet
Pms-Domperidone 10 mg Tablet0.15USD tablet
Ran-Domperidone 10 mg Tablet0.15USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)242.5 °CVanderberk, J., Kennis, L.E.J., Van der Aa, M.J.M.C. and Van Heertum, A.H.M.T.; U.S. Patents 4,066,772; January 3,1978; 4.1 10,333; August 29,1978; 4,126,687; November 21, 1978; 4,126,688; November 21,1978; 4,160,836; July 10,1979 and 4,175,129; November 20,1979; all assigned to Janssen Pharmaceutica NV (Belgium).
water solubility0.986 mg/LNot Available
logP3.90EL TAYER,N ET AL. (1985)
pKa7.9EL TAYAR,N ET AL. (1985)
Predicted Properties
PropertyValueSource
Water Solubility0.0925 mg/mLALOGPS
logP3.7ALOGPS
logP2.9ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)12.52ChemAxon
pKa (Strongest Basic)7.03ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area67.92 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity119.37 m3·mol-1ChemAxon
Polarizability45.61 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9967
Blood Brain Barrier+0.8686
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.7029
P-glycoprotein inhibitor IInhibitor0.7244
P-glycoprotein inhibitor IIInhibitor0.628
Renal organic cation transporterInhibitor0.6546
CYP450 2C9 substrateNon-substrate0.7974
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateSubstrate0.6392
CYP450 1A2 substrateInhibitor0.8737
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8933
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.5577
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8695
Ames testNon AMES toxic0.6608
CarcinogenicityNon-carcinogens0.922
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.9828 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.7527
hERG inhibition (predictor II)Inhibitor0.917
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00xr-0700900000-fbaf0980af220c88125f
MS/MS Spectrum - , positiveLC-MS/MSsplash10-004i-0300900000-912de932579a7a2a6e2f
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-004i-0900300000-877326ac38180c1229cd

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzimidazoles. These are organic compounds containing a benzene ring fused to an imidazole ring (five member ring containing a nitrogen atom, 4 carbon atoms, and two double bonds).
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzimidazoles
Sub Class
Not Available
Direct Parent
Benzimidazoles
Alternative Parents
Piperidines / N-substituted imidazoles / Benzenoids / Aryl chlorides / Heteroaromatic compounds / Ureas / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds
show 3 more
Substituents
Benzimidazole / Aryl chloride / Aryl halide / N-substituted imidazole / Piperidine / Benzenoid / Azole / Imidazole / Heteroaromatic compound / Tertiary aliphatic amine
show 14 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
benzimidazoles, heteroarylpiperidine (CHEBI:31515)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Cavallotti C, Nuti F, Bruzzone P, Mancone M: Age-related changes in dopamine D2 receptors in rat heart and coronary vessels. Clin Exp Pharmacol Physiol. 2002 May-Jun;29(5-6):412-8. [PubMed:12010185]
  2. Osinski MA, Uchic ME, Seifert T, Shaughnessy TK, Miller LN, Nakane M, Cox BF, Brioni JD, Moreland RB: Dopamine D2, but not D4, receptor agonists are emetogenic in ferrets. Pharmacol Biochem Behav. 2005 May;81(1):211-9. [PubMed:15894081]
  3. de Mey C, Enterling D, Meineke I, Yeulet S: Interactions between domperidone and ropinirole, a novel dopamine D2-receptor agonist. Br J Clin Pharmacol. 1991 Oct;32(4):483-8. [PubMed:1683559]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  5. Ali I, Gupta VK, Singh P, Pant HV: Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31. doi: 10.1016/j.talanta.2005.06.027. Epub 2005 Jul 22. [PubMed:18970411]
Details
2. D(3) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name
DRD3
Uniprot ID
P35462
Uniprot Name
D(3) dopamine receptor
Molecular Weight
44224.335 Da
References
  1. Freedman SB, Patel S, Marwood R, Emms F, Seabrook GR, Knowles MR, McAllister G: Expression and pharmacological characterization of the human D3 dopamine receptor. J Pharmacol Exp Ther. 1994 Jan;268(1):417-26. [PubMed:8301582]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Chang SY, Fancher RM, Zhang H, Gan J: Mechanism-based inhibition of human cytochrome P4503A4 by domperidone. Xenobiotica. 2010 Feb;40(2):138-45. doi: 10.3109/00498250903406762. [PubMed:20082577]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Simard C, Michaud V, Gibbs B, Masse R, Lessard E, Turgeon J: Identification of the cytochrome P450 enzymes involved in the metabolism of domperidone. Xenobiotica. 2004 Nov-Dec;34(11-12):1013-23. [PubMed:15801545]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. [PubMed:12954186]
  2. Schinkel AH, Wagenaar E, Mol CA, van Deemter L: P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest. 1996 Jun 1;97(11):2517-24. [PubMed:8647944]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34